HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

被引：0
|
作者：
Catalina Falo
Abelardo Moreno
Mar Varela
Belen Lloveras
Agnès Figueras
Agustín Escobedo
机构：
[1] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[2] Hospital Universitari de Bellvitge,Department of Medical Oncology, Breast Cancer Unit, Institut Català d’Oncologia
[3] Hospital Duran i Reynals,Department of Pathology, Breast Cancer Unit
[4] Hospital Universitari de Bellvitge,Tumour Bank, Institut Català d’Oncologia
[5] Hospital Duran i Reynals,Department of Pathology, Institut Català d’Oncologia
[6] Hospital Duran i Reynals,Translational Research Laboratory, Institut Català d’Oncologia
[7] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[8] Hospital Duran i Reynals,Unitat Funcional de Mama
[9] Institut Català d’Oncologia,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2007年 / 133卷
关键词：
Breast carcinoma; Her-2/; Primary chemotherapy; Response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：423 / 429
页数：6
相关论文
共 50 条
  • [1] HER-2/neu status and response to CMF:: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy
    Falo, Catalina
    Moreno, Abelardo
    Varela, Mar
    Lloveras, Belen
    Figueras, Agnes
    Escobedo, Agustin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (07) : 423 - 429
  • [2] Predictive value of HER-2 status in advanced breast cancer for the response to CMF chemotherapy
    Neskovic-Konstantinovic, Z.
    Susnjar, S.
    Todorovic-Rakovic, N.
    Jovanovic, D.
    Nikolic-Vukosavljevic, D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 123 - 123
  • [3] HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
    Konecny, G
    Fritz, M
    Untch, M
    Lebeau, A
    Felber, M
    Lude, S
    Beryt, M
    Hepp, H
    Slamon, D
    Pegram, M
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (01) : 53 - 63
  • [4] HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer
    Gottfried Konecny
    Manuel Fritz
    Michael Untch
    Annette Lebeau
    Margrit Felber
    Sandra Lude
    Malgorzata Beryt
    Hermann Hepp
    Dennis Slamon
    Mark Pegram
    Breast Cancer Research and Treatment, 2001, 69 : 53 - 63
  • [5] Response to CMF according to HER-2 overexpression
    de Boer R.
    Breast Cancer Research, 3 (1)
  • [6] Predictive parameters of response in primary CMF chemotherapy of breast cancer
    Escobedo, A
    Moreno, A
    Loveras, B
    Figueras, A
    Riu, F
    Gimenez, C
    Prieto, L
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S25 - S25
  • [7] Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
    Mokhtari, Maral
    Khosravi, Mohammad Hadi
    MIDDLE EAST JOURNAL OF CANCER, 2021, 12 (04) : 483 - 490
  • [8] PRESENT STATUS OF CMF ADJUVANT THERAPY IN OPERABLE BREAST-CANCER
    BONADONNA, G
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (3-4): : 237 - 240
  • [9] ADJUVANT CMF CHEMOTHERAPY IN OPERABLE BREAST-CANCER - 10 YEARS LATER
    BONADONNA, G
    ROSSI, A
    VALAGUSSA, P
    LANCET, 1985, 1 (8435): : 976 - 977
  • [10] ADJUVANT CMF CHEMOTHERAPY IN OPERABLE BREAST-CANCER - 10 YEARS LATER
    BONADONNA, G
    ROSSI, A
    VALAGUSSA, P
    WORLD JOURNAL OF SURGERY, 1985, 9 (05) : 707 - 713
12345